TEVA stock forecast, quote, news & analysis

Key Takeaways

• Teva Pharmaceutical Industries (TEVA) shares closed near $42 in late October 2026, up roughly 6% over the trailing 30 days.
• The recent climb extends a broader multi-month uptrend, with the stock up approximately 19% from its late-July level.
• Growth is being powered by Teva's innovative portfolio — AUSTEDO, AJOVY, and UZEDY — whose combined revenue rose 43% year over year in the second quarter of 2026.
• Generics revenue remains a headwind, down 15% year over year in Q2 2026, largely due to a lower contribution from generic Revlimid.
• Management raised the midpoint of its full-year 2026 revenue guidance by $75 million while adjusting profit outlooks to reflect the Emalex Biosciences acquisition.
• For additional detail on valuation and forward estimates, explore the company's Price Targets, Earnings, and Forecast pages.
• Interested in automated strategies? Explore Trending AI Robots to see curated, top-performing AI trading bots.

Current Market Snapshot

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has traded with a constructive tone through late 2026. After a strong upward move in July following its second-quarter results, the stock consolidated through September before resuming its climb in October, finishing the month near the $42 level. The modest, steady advance of roughly 6% over the trailing 30 days stands in contrast to sharper sector swings, suggesting measured accumulation rather than a single event-driven spike.

Broader sentiment around Teva has improved as investors increasingly credit the company's "Pivot to Growth" strategy, which emphasizes branded innovative medicines and biosimilars over its legacy generics franchise. The company's progress on debt reduction and free cash flow generation has also supported a more favorable view of the equity, even as near-term generic headwinds persist.

Teva Pharmaceutical Industries (TEVA) Business Overview and Competitive Position

Teva Pharmaceutical Industries is one of the world's largest pharmaceutical companies, headquartered in Israel with a substantial U.S. manufacturing and commercial presence. The company's business spans generic medicines, specialty innovative therapies, and a growing biosimilars platform. Its generics scale and broad distribution reach have long made it a leading supplier to pharmacies and health systems globally.

In recent years, Teva has refocused its growth narrative around a trio of innovative brands. AUSTEDO, a treatment for tardive dyskinesia and Huntington's disease chorea, is the company's flagship growth driver. AJOVY, a migraine therapy, and UZEDY, a long-acting injectable for schizophrenia, round out the portfolio. Together these products are reshaping Teva's revenue mix and margins. The company is also building out biosimilars — with 15 products already on the market and 14 more in its pipeline — positioning itself to benefit from patent expiries across the biologics landscape.

Recent Developments Driving TEVA

Teva's most significant recent development was its second-quarter 2026 earnings report, released in late July. Revenue came in at approximately $4.1 billion, down 1% year over year in U.S. dollars, as a steep decline in generic Revlimid sales offset strong growth in innovative medicines. The innovative portfolio delivered combined growth of 43% year over year, led by AUSTEDO, AJOVY, and UZEDY.

Management raised full-year 2026 revenue guidance for all three key brands and increased the midpoint of its overall revenue outlook by $75 million. AUSTEDO's 2026 revenue guidance was lifted to a range of $2.45 billion to $2.6 billion, AJOVY's to $850 million to $870 million, and UZEDY's to $270 million to $290 million.

The quarter also reflected the impact of Teva's acquisition of Emalex Biosciences, recorded as an asset acquisition with a roughly $724 million in-process research and development charge. As a result, Teva reported a GAAP net loss for the quarter, while revising its full-year non-GAAP operating income and earnings per share outlooks lower to reflect the deal. On an underlying basis, excluding the Emalex-related impact, non-GAAP earnings per share would have been about $0.63.

Elsewhere, Teva highlighted progress on biosimilars, noting it expects to exceed its $800 million biosimilar revenue target by 2027, and signaled a potential fourth-quarter FDA decision on its long-acting injectable olanzapine product.

Trending AI Robots

Tickeron's Trending AI Robots page offers a curated view into a marketplace of hundreds of AI-driven trading bots that track thousands of tickers. Rather than listing every available strategy, the page surfaces only the top-performing and most relevant bots, making it easier for traders to identify systems that are currently generating strong results. These bots vary widely in their approach, trading timeframe, and performance metrics, so the section provides a useful way to compare different strategies at a glance. For those interested in automated, data-driven approaches to the market, exploring this curated selection can be a practical starting point.

2026 Outlook and What Investors Should Watch

Looking ahead, Teva's next earnings report, expected around mid-November 2026, will be a key checkpoint for investors. Attention will focus on whether AUSTEDO, AJOVY, and UZEDY can sustain their momentum, whether generic pricing pressures stabilize, and how management frames the impact of the Emalex acquisition on near-term profitability.

Other factors worth monitoring include the potential U.S. launch of Teva's long-acting injectable olanzapine, the continued build-out of its biosimilars pipeline, and progress toward its 2027 financial targets, which include a non-GAAP operating margin goal of 30% and further debt reduction. Regulatory and policy developments affecting U.S. drug pricing and reimbursement, as well as foreign-exchange fluctuations, remain important variables that could influence both financial results and investor sentiment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations